Responses
Basic and translational research
Extended report
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Compose a Response to This Article
Other responses
No responses have been published for this article.